Business Description
Cellid Co Ltd
ISIN : KR7299660001
Share Class Description:
XKRX:299660: Ordinary SharesCompare
Compare
Traded in other countries / regions
299660.Korea IPO Date
2019-02-20Description
Cellid Co Ltd is a research and development bioventure company. The company is developing immunotherapeutic vaccines, CeliVax. The CeliVax is a personalized vaccine which uses patient's own cells.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -2.24 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -29.5 | |||||
| 3-Year EPS without NRI Growth Rate | -45 | |||||
| 3-Year FCF Growth Rate | -6.8 | |||||
| 3-Year Book Growth Rate | -11.3 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.04 | |||||
| 9-Day RSI | 51.12 | |||||
| 14-Day RSI | 52.08 | |||||
| 6-1 Month Momentum % | 67.24 | |||||
| 12-1 Month Momentum % | 12.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.15 | |||||
| Quick Ratio | 5.15 | |||||
| Days Inventory | 30.14 | |||||
| Days Sales Outstanding | 31.35 | |||||
| Days Payable | 55.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7 | |||||
| Shareholder Yield % | -1.36 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 18.31 | |||||
| Operating Margin % | -341.58 | |||||
| Net Margin % | -440.53 | |||||
| FCF Margin % | -1112.15 | |||||
| ROE % | -25.51 | |||||
| ROA % | -16.42 | |||||
| ROIC % | -13.75 | |||||
| ROC (Joel Greenblatt) % | -19.12 | |||||
| ROCE % | -11.64 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 34.68 | |||||
| PB Ratio | 2.25 | |||||
| Price-to-Tangible-Book | 2.19 | |||||
| EV-to-EBIT | -18.78 | |||||
| EV-to-EBITDA | -26.74 | |||||
| EV-to-Revenue | 51.02 | |||||
| EV-to-FCF | -5.67 | |||||
| Earnings Yield (Greenblatt) % | -5.32 | |||||
| FCF Yield % | -20.84 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cellid Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 2,283.424 | ||
| EPS (TTM) (â‚©) | -627 | ||
| Beta | 1.42 | ||
| Volatility % | 135.68 | ||
| 14-Day RSI | 52.08 | ||
| 14-Day ATR (â‚©) | 716.698729 | ||
| 20-Day SMA (â‚©) | 5225.25 | ||
| 12-1 Month Momentum % | 12.14 | ||
| 52-Week Range (â‚©) | 1733 - 17310 | ||
| Shares Outstanding (Mil) | 21.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cellid Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cellid Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cellid Co Ltd Frequently Asked Questions
What is Cellid Co Ltd(XKRX:299660)'s stock price today?
The current price of XKRX:299660 is â‚©5690.00. The 52 week high of XKRX:299660 is â‚©17310.00 and 52 week low is â‚©1733.00.
When is next earnings date of Cellid Co Ltd(XKRX:299660)?
The next earnings date of Cellid Co Ltd(XKRX:299660) is .
Does Cellid Co Ltd(XKRX:299660) pay dividends? If so, how much?
Cellid Co Ltd(XKRX:299660) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers